LabCorp
SPECIMEN INFORMATION
SPECIMEN: 22717424600
LAB REF NO:
COLLECTED: 2013-08-15
RECEIVED: 2013-08-15
REPORTED: 2013-08-18
AGE: 38
GENDER: Male
FASTING: Yes
Clinical Info:
REPORT STATUS: FINAL
ORDERING PHYSICIAN
CLIENT INFORMATION
2013-08-18 17:06:00 -0700
MEDIVO, INC.
55 Broad Street
16th Floor
New York, NY 10004
Test Name Result Flag Reference Range Lab
CBC With Differential/Platelet
WBC 3.5 LOW 4.0-10.5 x10E3/uL BN
RBC 4.58 4.14-5.80 x10E6/uL BN
Hemoglobin 13.5 12.6-17.7 g/dL BN
Hematocrit 40.6 37.5-51.0 % BN
MCV 89 79-97 fL BN
MCH 29.5 26.6-33.0 pg BN
MCHC 33.3 31.5-35.7 g/dL BN
RDW 14.0 12.3-15.4 % BN
Platelets 227 140-415 x10E3/uL BN
Neutrophils 44 40-74 % BN
Lymphs 44 14-46 % BN
Monocytes 9 4-13 % BN
Eos 2 0-7 % BN
Basos 1 0-3 % BN
Neutrophils (Absolute) 1.5 LOW 1.8-7.8 x10E3/uL BN
Lymphs (Absolute) 1.5 0.7-4.5 x10E3/uL BN
Monocytes(Absolute) 0.3 0.1-1.0 x10E3/uL BN
Eos (Absolute) 0.1 0.0-0.4 x10E3/uL BN
Baso (Absolute) 0.0 0.0-0.2 x10E3/uL BN
Immature Granulocytes 0 0-2 % BN
Immature Grans (Abs) 0.0 0.0-0.1 x10E3/uL BN
Comp. Metabolic Panel (14)
Glucose, Serum 90 65-99 mg/dL BN
BUN 18 6-20 mg/dL BN
Creatinine, Serum 0.72 LOW 0.76-1.27 mg/dL BN
eGFR If NonAfricn Am 118 >59 mL/min/1.73 BN
eGFR If Africn Am 137 >59 mL/min/1.73 BN
BUN/Creatinine Ratio 25 HIGH 8-19 BN
Sodium, Serum 141 134-144 mmol/L BN
Potassium, Serum 3.9 3.5-5.2 mmol/L BN
Chloride, Serum 105 97-108 mmol/L BN
Carbon Dioxide, Total 24 19-28 mmol/L BN
Calcium, Serum 9.0 8.7-10.2 mg/dL BN
Protein, Total, Serum 6.8 6.0-8.5 g/dL BN
Albumin, Serum 4.2 3.5-5.5 g/dL BN
Globulin, Total 2.6 1.5-4.5 g/dL BN
A/G Ratio 1.6 1.1-2.5 BN
Bilirubin, Total 0.6 0.0-1.2 mg/dL BN
Alkaline Phosphatase, S 64 44-102 IU/L BN
AST (SGOT) 27 0-40 IU/L BN
ALT (SGPT) 36 0-44 IU/L BN
Lipid Panel
Cholesterol, Total 166 100-199 mg/dL BN
Triglycerides 38 0-149 mg/dL BN
HDL Cholesterol 54 >39 mg/dL BN
According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a
negative risk factor for CHD.
VLDL Cholesterol Cal 8 5-40 mg/dL BN
LDL Cholesterol Calc 104 HIGH 0-99 mg/dL BN
Thyroid Panel With TSH
1 of 2
TSH 1.080 0.450-4.500 uIU/mL BN
Thyroxine (T4) 8.2 4.5-12.0 ug/dL BN
T3 Uptake 37 24-39 % BN
Free Thyroxine Index 3.0 1.2-4.9 BN
Testosterone, Free/Tot Equilib
Testosterone, Serum 397 348-1197 ng/dL BN
Testosterone,Free 12.98 5.00-21.00 ng/dL BN
% Free Testosterone 3.27 1.50-4.20 % BN
Prostate-Specific Ag, Serum
Prostate Specific Ag, Serum 0.8 0.0-4.0 ng/mL BN
Roche ECLIA methodology.
.
According to the American Urological Association, Serum PSA should
decrease and remain at undetectable levels after radical
prostatectomy. The AUA defines biochemical recurrence as an initial
PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used
interchangeably. Results cannot be interpreted as absolute evidence
of the presence or absence of malignant disease.
IGF-1
Insulin-Like Growth Factor I 165 69-226 ng/mL BN
Estradiol, Sensitive
Estradiol, Sensitive 5 3-70 pg/mL BN
Male Female
0- 6 yrs. 0 - 15 0 - 15
7-10 yrs. 0 - 15 0 - 70
11-12 yrs. 0 - 40 10 - 300
13-15 yrs. 0 - 45 10 - 300
>15 yrs. 3 - 70 See Below
Ovulating Female
Follicular Phase 9 - 175
Luteal Phase 44 - 196
Periovulatory 107 - 281
Oral Contraceptives 0 - 91
Postmenopausal
Treated 42 - 289
Untreated 0 - 19
.
Estradiol results obtained with different
assay methods cannot be used interchangeably.
It is recommended that only one assay method
be used consistently to monitor serial
patient results.
Performing Laboratory Information:
BN: LabCorp Burlington, 1447 York Court, Burlington NC, phone: 800-762-4344
Medical Director: MD William F Hancock
2 of 2
SPECIMEN INFORMATION
SPECIMEN: 22717424600
LAB REF NO:
COLLECTED: 2013-08-15
RECEIVED: 2013-08-15
REPORTED: 2013-08-18
AGE: 38
GENDER: Male
FASTING: Yes
Clinical Info:
REPORT STATUS: FINAL
ORDERING PHYSICIAN
CLIENT INFORMATION
2013-08-18 17:06:00 -0700
MEDIVO, INC.
55 Broad Street
16th Floor
New York, NY 10004
Test Name Result Flag Reference Range Lab
CBC With Differential/Platelet
WBC 3.5 LOW 4.0-10.5 x10E3/uL BN
RBC 4.58 4.14-5.80 x10E6/uL BN
Hemoglobin 13.5 12.6-17.7 g/dL BN
Hematocrit 40.6 37.5-51.0 % BN
MCV 89 79-97 fL BN
MCH 29.5 26.6-33.0 pg BN
MCHC 33.3 31.5-35.7 g/dL BN
RDW 14.0 12.3-15.4 % BN
Platelets 227 140-415 x10E3/uL BN
Neutrophils 44 40-74 % BN
Lymphs 44 14-46 % BN
Monocytes 9 4-13 % BN
Eos 2 0-7 % BN
Basos 1 0-3 % BN
Neutrophils (Absolute) 1.5 LOW 1.8-7.8 x10E3/uL BN
Lymphs (Absolute) 1.5 0.7-4.5 x10E3/uL BN
Monocytes(Absolute) 0.3 0.1-1.0 x10E3/uL BN
Eos (Absolute) 0.1 0.0-0.4 x10E3/uL BN
Baso (Absolute) 0.0 0.0-0.2 x10E3/uL BN
Immature Granulocytes 0 0-2 % BN
Immature Grans (Abs) 0.0 0.0-0.1 x10E3/uL BN
Comp. Metabolic Panel (14)
Glucose, Serum 90 65-99 mg/dL BN
BUN 18 6-20 mg/dL BN
Creatinine, Serum 0.72 LOW 0.76-1.27 mg/dL BN
eGFR If NonAfricn Am 118 >59 mL/min/1.73 BN
eGFR If Africn Am 137 >59 mL/min/1.73 BN
BUN/Creatinine Ratio 25 HIGH 8-19 BN
Sodium, Serum 141 134-144 mmol/L BN
Potassium, Serum 3.9 3.5-5.2 mmol/L BN
Chloride, Serum 105 97-108 mmol/L BN
Carbon Dioxide, Total 24 19-28 mmol/L BN
Calcium, Serum 9.0 8.7-10.2 mg/dL BN
Protein, Total, Serum 6.8 6.0-8.5 g/dL BN
Albumin, Serum 4.2 3.5-5.5 g/dL BN
Globulin, Total 2.6 1.5-4.5 g/dL BN
A/G Ratio 1.6 1.1-2.5 BN
Bilirubin, Total 0.6 0.0-1.2 mg/dL BN
Alkaline Phosphatase, S 64 44-102 IU/L BN
AST (SGOT) 27 0-40 IU/L BN
ALT (SGPT) 36 0-44 IU/L BN
Lipid Panel
Cholesterol, Total 166 100-199 mg/dL BN
Triglycerides 38 0-149 mg/dL BN
HDL Cholesterol 54 >39 mg/dL BN
According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a
negative risk factor for CHD.
VLDL Cholesterol Cal 8 5-40 mg/dL BN
LDL Cholesterol Calc 104 HIGH 0-99 mg/dL BN
Thyroid Panel With TSH
1 of 2
TSH 1.080 0.450-4.500 uIU/mL BN
Thyroxine (T4) 8.2 4.5-12.0 ug/dL BN
T3 Uptake 37 24-39 % BN
Free Thyroxine Index 3.0 1.2-4.9 BN
Testosterone, Free/Tot Equilib
Testosterone, Serum 397 348-1197 ng/dL BN
Testosterone,Free 12.98 5.00-21.00 ng/dL BN
% Free Testosterone 3.27 1.50-4.20 % BN
Prostate-Specific Ag, Serum
Prostate Specific Ag, Serum 0.8 0.0-4.0 ng/mL BN
Roche ECLIA methodology.
.
According to the American Urological Association, Serum PSA should
decrease and remain at undetectable levels after radical
prostatectomy. The AUA defines biochemical recurrence as an initial
PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used
interchangeably. Results cannot be interpreted as absolute evidence
of the presence or absence of malignant disease.
IGF-1
Insulin-Like Growth Factor I 165 69-226 ng/mL BN
Estradiol, Sensitive
Estradiol, Sensitive 5 3-70 pg/mL BN
Male Female
0- 6 yrs. 0 - 15 0 - 15
7-10 yrs. 0 - 15 0 - 70
11-12 yrs. 0 - 40 10 - 300
13-15 yrs. 0 - 45 10 - 300
>15 yrs. 3 - 70 See Below
Ovulating Female
Follicular Phase 9 - 175
Luteal Phase 44 - 196
Periovulatory 107 - 281
Oral Contraceptives 0 - 91
Postmenopausal
Treated 42 - 289
Untreated 0 - 19
.
Estradiol results obtained with different
assay methods cannot be used interchangeably.
It is recommended that only one assay method
be used consistently to monitor serial
patient results.
Performing Laboratory Information:
BN: LabCorp Burlington, 1447 York Court, Burlington NC, phone: 800-762-4344
Medical Director: MD William F Hancock
2 of 2
Last edited:
